Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate ...

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma.

CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing ...

芝加哥和德克萨斯州沃思堡 - 临床阶段生物制药公司Actuate Therapeutics, Inc. (NASDAQ: ACTU)宣布,美国食品和药物管理局(FDA)已授予其研究性药物elraglusib用于软组织肉瘤(STS)治疗的孤儿药资格认定(ODD)。这一认定是elraglusib的重要里程碑,该药物是一种新型的糖原合成酶激酶-3β(GSK-3β)抑制剂,GSK-3β是一种参与肿瘤生长和 ...

FDA 已授予 elraglusib 孤儿药资格（ODD），用于治疗软组织肉瘤（STS）患者。 目前，一项 2 期开放标签 2 层试验正在评估 elraglusib 与吉西他滨和多西他赛联合治疗 10 ...

There are many ways to increase power under the hood of your car, but some are simpler than others. Here's what you should ...

Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 21% phase transition ...

But that fact of life, something that absolutely is fact, makes BMW's decision to make the standard R 1300 GS' shifter out of ...

The wireless Kone II Air mouse isn't quite as sharp as its wired counterpart, but still finds a good balance between ergonomics and gaming.

Fort Worth, Texas, clinical-stage biopharmaceutical company Actuate said elraglusib has shown a favorable safety profile and antitumor activity across several solid tumors, including melanoma, Ewing ...

CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...